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Notch signaling plays a key role in various cell differentiation processes including bone homeostasis.
However, the specific involvement of Notch in regulating osteoclastogenesis is still controversial. In the present
study, we show that RANKL induces expression of Jagged1 and Notch2 in bone marrow macrophages during
osteoclast differentiation. Suppression of Notch signaling by a selective -secretase inhibitor or Notch2 short
hairpin RNA suppresses RANKL-induced osteoclastogenesis. In contrast, induction of Notch signaling by
Jagged1 or by ectopic expression of intracellular Notch2 enhances NFATc1 promoter activity and expression
and promotes osteoclastogenesis. Finally, we found that Notch2 and p65 interact in the nuclei of RANKL-
stimulated cells and that both proteins are recruited to the NFATc1 promoter, driving its expression. Taken
together, our results show a new molecular cross talk between Notch and NF-B pathways that is relevant in
osteoclastogenesis.
Osteoclasts are bone-resorbing multinucleated cells derived
from the monocyte-macrophage lineage (5, 8, 56). The differ-
entiation and activation of osteoclasts are closely regulated by
osteoblasts or bone marrow-derived stromal cells (8, 56). Re-
ceptor activator of NF-B ligand (RANKL) and macrophage
colony-stimulating factor (M-CSF) are both crucial for osteo-
clast development (8, 56). RANKL is a member of the tumor
necrosis factor (TNF) family of cytokines, and its expression is
regulated by a number of bone-resorbing factors including
1,25-dihydroxyvitamin D3 [1,25(OH)2D3], interleukin-1 (IL-
1), IL-6, and TNF-. M-CSF induces the proliferation and
survival of monocyte/macrophage osteoclast precursor cells,
whereas RANKL mainly regulates differentiation and activa-
tion of these precursors (5).
RANK is expressed as a transmenbrane heterotrimer on the
surfaces of hematopoietic osteoclast progenitors and mature
osteoclasts. The in vivo significance of the RANKL-RANK
signaling pathway has been verified in mice by targeted disrup-
tion of either of the associated genes, which results in severe
osteopetrosis and a total lack of osteoclasts (14, 29). Although
the RANK cytoplasmic domain interacts with various TNF
receptor-associated factors (TRAFs) (TRAF1 to -6, except for
TRAF4) only TRAF6 is essential for RANK-dependent oste-
oclast differentiation, as evidenced by the osteopetrosis devel-
oped in mice lacking TRAF6 (41). The RANKL-RANK inter-
action promotes osteoclast differentiation through activation
of several intracellular pathways including nuclear factor of
activated T cells (NFAT) (55), NF-B (18, 25), Fos (19), and
mitogen-activated protein kinase (24) pathways. In agreement
with this, c-Fos-deficient mice and NF-B p50 and p52 double-
knockout mice developed typical osteopetrosis, accompanied
by growth retardation, excessive calcification in the long bones,
and impaired tooth eruption due to lack of osteoclasts. Re-
cently, Asagiri et al. demonstrated the requirement for
NFATc1 in the generation of osteoclasts in vivo by transferring
NFATc1-deficient hematopoietic stem cells into c-Fos-defi-
cient mice (4). Recent studies showed that, in addition to
RANKL-RANK signaling, other costimulatory signals such as
those involving multiple immunoglobulin-like receptors asso-
ciated with immunoreceptor tyrosine-based activation motif-
harboring adapters, Fc receptor common  chain subunit
(FcR), and DNAX-activating protein 12 are important in
regulating osteoclast differentiation (28). Furthermore, cal-
cineurin-NFATc1 calcium signaling activates the calcium/cal-
modulin-activated kinase–CREB (cyclic AMP response ele-
ment binding protein) pathway, which also plays a critical role
in osteoclastogenesis (46).
Notch signaling is a highly conserved signaling pathway that
plays a critical role in a variety of cellular functions including
cell proliferation, differentiation, and apoptosis (3). In verte-
brates, four Notch receptors (Notch1 to -4) and five ligands
(Delta1, -3, and -4 and Jagged1 and -2) have been identified;
all are single-span transmembrane polypeptides that respond
to cell-cell interactions (9). Notch receptors contain multiple
epidermal growth factor-like repeats and three cysteine-rich
Notch/LIN-12 repeats in the extracellular domain, whereas the
intracellular domain contains seven cdc10/ankyrin repeats, a
glutamine-rich domain, and a PEST sequence. Notch ligands
also have epidermal growth factor repeats in the extracellular
domain in addition to a unique cysteine-rich N-terminal re-
gion, referred to as the Delta:Serrate:LAG2 domain, and a
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small intracellular domain. Notch is activated through binding
to the appropriate ligand present on neighboring cells, which
results in the proteolytic cleavage of Notch receptor by presen-
ilin/-secretase and the nuclear translocation of the Notch
intracellular domain (NICD) (3, 9). Once in the nucleus,
NICD interacts with the DNA-binding protein CSL [named for
CBF1/RBPJ, Su (H), and LAG1] and activates transcription
of its target genes such as the hairy enhancer of split 1 (HES-1)
and HES-5 genes (20). Alternatively, it has been reported to
transmit signals through CSL-independent pathways by inter-
acting with other signaling molecules, such as phosphatidylino-
sitol 3-kinase, Src, and NF-B (40, 50, 51, 52, 58).
Mice deficient in several Notch family members such as
Notch1, Notch2, Jagged1, and Delta1 die during embryogen-
esis before bone formation (23, 36, 53, 61); thus, it is impos-
sible to use these models for the study of osteoclastogenesis.
However, multiple pieces of evidence indicate that Notch sig-
naling dysfunction results in bone disease. For example, pre-
senilin 1-deficient mice and Delta3 mutant mice (Pudgy) ex-
hibit axial skeletal defects (10, 30, 35, 48) and Alagille
syndrome (OMIM no. 118450 and 610205), which is caused by
mutation in the Jagged1 or Notch2 gene and is characterized
by the presence of “butterfly” vertebrae (36, 37, 38). Moreover,
parathyroid hormone/parathyroid hormone-related peptide re-
ceptor transgenic mice that show increased Jagged1 expression
in the osteoblastic stromal cells and contain a higher number of
NICD-positive hematopoietic stem cells in bone marrow than
wild-type mice display increased trabecular bone volume and
decreased cortical bone thickness of the long bones (11, 12). In
addition, in vitro studies also support a role for the Notch
pathway in osteoblastogenesis and bone formation (13, 43, 47,
57, 63). Recently two different groups demonstrated that spe-
cific deletion of presenilin 1 and 2 in the skeletogenic mesen-
chyme in the limb and the calvaria leads to increased trabec-
ular bone mass. At the biochemical level, they showed that
Notch signaling inhibits osteoblast differentiation by repressing
the Runx2 transactivation function. Furthermore, knockout
mice developed an age-related osteoporosis resulting from in-
creased osteoclastic activity, likely due to decreased osteoprog-
erin mRNA expression (15, 21). These results are in agreement
with previous in vitro data showing that Notch activation by
Delta1 reduces the surface levels of the M-CSF receptor, c-
Fms, in osteoclast precursor cells and enhances the expression
of osteoprogerin in stromal cells, resulting in the downregula-
tion of osteoclastogenesis (62).
To further study the functional involvement of Notch in
RANKL-dependent osteoclastogenesis, we first analyzed the
expression patterns and the activation status of several Notch
family members and determined the effects of inhibiting or
activating the Notch pathway at different stages of osteoclast
differentiation. In addition, we addressed the molecular mech-
anisms by which Notch modulates RANKL-induced osteoclas-
togenesis at the chromatin level.
MATERIALS AND METHODS
Animals. This study was approved by the Council on Animal Care and Gene
Transfer at Fukuoka Dental College. Male ddY mice (3 to 5 weeks old) were
purchased from the Kyudo (Tosu, Saga, Japan). Mice were housed at the Animal
Center of Fukuoka Dental College.
Reagents. Recombinant human RANKL and M-CSF were purchased from
PeproTech Inc. (Rocky Hill, NJ). -Secretase inhibitor X (L685,458) (GSI), a
selective inhibitor of Notch signaling, was purchased from Calbiochem (La, Jolla,
CA). Cleaved Notch1 (Val1744) and anti-Notch1 antibodies (C-20) were pur-
chased from Cell Signaling (Beverly, MA) and Santa Cruz Biotechnology (Santa
Cruz, CA), respectively. The anti-Notch2 antibody (C651.6DbHN) was pur-
chased from Developmental Studies Hybridoma Bank (University of Iowa, Iowa
City). The anti-RBPJ antibody was purchased from the Institute of Immunology
(Tokyo, Japan). Anti-NFATc1, -p65, -p50, -RANK, -IB, -histone deacetylase
1 (HDAC1), and -c-Fos antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). FLAG-fused human Jagged1 (Jagged-1 FL) was
cloned and then purified as described previously (43, 62).
Cell culture. Bone marrow-derived macrophages (BMMs) were prepared as
osteoclast precursors from 3- to 5-week-old male ddY mice. Bone marrow cells
obtained from the mouse tibia were suspended in 60-mm-diameter dishes for
16 h in the presence of M-CSF (50 ng/ml) in -minimal essential medium
containing 10% fetal bovine serum. Then, nonadherent cells were harvested and
further cultured for 2 days with M-CSF (50 ng/ml). The adherent cells, most of
which expressed macrophage-specific antigens such as Mac-1, Moma-2, and
F4/80, were used as BMMs. BMMs were cultured for 3 days with RANKL (50
ng/ml). The macrophage cell line RAW 264.7 (RAW cells) (ATCC, Manassas,
VA) was cultured for 3 days with RANKL (20 ng/ml). Cultures were fixed with
3.7% formaldehyde, and osteoclasts were detected by staining for tartrate-resis-
tant acid phosphatase (TRAP). TRAP-positive multinucleated cells (MNCs)
containing more than three nuclei were observed under a microscope and
counted as osteoclasts. Soluble or immobilized Jagged1 was used as described
elsewhere (43, 62).
Gene chip analysis. RAW cells were stimulated for 3 days with or without
RANKL (20 ng/ml). Total RNA from untreated or RANKL-treated RAW cells
was extracted from three independent experiments using Trizol (Invitrogen,
Carlsbad, CA). Total RNA (15 g) was used for cDNA synthesis by reverse
transcription followed by synthesis of biotinylated cRNA via in vitro transcrip-
tion. After cRNA fragmentation, hybridization with a mouse U74Av2 GeneChip
(Affymetrix, Santa Clara, CA) displaying probes for 12,000 mouse genes/ex-
pressed sequence tags was performed according to the manufacturer’s protocol.
Chips were washed, stained with streptavidin-phycoerythrin, and analyzed using
a scanner and accompanying gene expression software GeneSpring (Agilent
Technologies, Santa Clara, CA).
TABLE 1. Genes preferentially expressed in RAW264.7
cell-derived osteoclasts
Group Entrez gene symbol GenBankaccession no.
Fold
increasea









Notch-dependent Hes-1 NM_008235 1.7




Osteoclast Calcitonin receptor NM_007588 6.8
markers TRAP NM_021330 7.1
Cathepsin K NM_007588 5.7
RANK NM_011613 3.9
NFATc1 NM_016791 4.4
a Increases in the mRNA expression level in RANKL-stimulated RAW cell-
derived osteoclasts compared with that in unstimulated RAW cells. GeneChip
analysis was repeated several times and yielded similar results; a representative
set of data is shown. The increases were calculated with GeneSpring.
b ND, not determined.
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PCR analysis. For reverse transcription-PCR (RT-PCR), total RNA prepared
using Trizol was amplified using Superscript II and Taq polymerase (Invitrogen).
Primer sequences were as described by Yamada et al. (62). The PCR conditions
were as follows: 94°C (3 min), 60°C (2 min), and 72°C (3 min) for the primary
cycle and 94°C (45 s), 60°C (1 min), and 72°C (1.5 min) for the following 30
cycles. The fluorescence of each PCR product was detected using an image
analyzer (fluoro image analyzer FLA-2000F; Fuji Film, Tokyo, Japan).
Coprecipitation and immunoblotting. Cells were lysed in TNT buffer (20 mM
Tris-HCl, pH 7.5, 200 mM NaCl, 1% Triton X-100, 1 mM dithiothreitol) con-
taining protease inhibitors (Roche, Basel, Switzerland). Cytosolic, membrane,
and nuclear fraction proteins were extracted from cells using a Calbiochem
Proteo Extract subcellular proteosome extraction kit (Merck KGaA, Darmstadt,
Germany) by following the manufacturer’s protocol. For coprecipitation exper-
iments, nuclear extracts were incubated for 6 h at 4°C with anti-Notch2 antibody
coupled to protein A/G-Sepharose beads. The immune complex was extensively
washed with TNT buffer, and samples were boiled and analyzed by immunoblot-
ting.
Protein content was measured with Pierce reagent by following the manufac-
turer’s protocol. Twenty micrograms of protein was subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene
difluoride membrane using 100 V for 1 h at 4°C. These membranes were then
incubated with antibodies at 1:500 to 1:1,000 dilutions in 5% dry milk solution
plus 0.01% azide overnight at 4°C. Subsequently, blots were washed in TTBS (10
mM Tris-HCl, 50 mM NaCl, 0.25% Tween 20) and incubated with a horseradish
peroxidase-conjugated secondary antibody. The immunoreactive proteins were
visualized using enhanced chemiluminescence (Amersham).
Immunofluorescence staining. Cells were fixed with 4% paraformaldehyde in
phosphate-buffered saline and incubated with 0.3% H2O2 in methanol for 30 min
followed by 10% horse serum for 1 h. The slides were then incubated with
primary antibodies for Notch1 and Notch2 overnight at 4°C. These primary
antibodies were detected by goat anti-rabbit Alexa 488 and goat anti-rat Alexa
568 (Molecular Probes) and visualized by fluorescence microscopy (TMD 300;
Nikon, Tokyo, Japan). After fluorescence analysis, cells were stained with TRAP
and nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI).
shRNA cell lines. For tetracycline-regulated expression of short hairpin RNAs
(shRNAs) (Tet-on) that target Notch1 and Notch2 constructs, we designed four
variant shRNAs to target the mRNA on a Block-iT RNA interference (RNAi)
designer (https://rnaidesigner.invitrogen.com/rnaiexpress) (Invitrogen). First,
double-stranded oligonucleotides that encoded the shRNAs were cloned into the
pENTR/H1/TO vector using a Block-iT inducible H1 RNAi entry vector kit by
following the manufacturer’s protocol (Invitrogen). We screened the pENTR/
H1/TO Notch1 and Notch2 shRNA clones by transfecting them into RAW cells
stably expressing pcDNA6/TR. Transfection was performed using Lipofectamine
2000 (Invitrogen), and cells were maintained in 50 g/ml blasticidin or 100 g/ml
zeocin (Invitrogen) for selection. Resistant cell lines were evaluated for their
ability to attenuate Notch1 and Notch2 expression by RT-PCR and immuno-
blotting. Four of the tested constructs were then used to attenuate Notch1 and
Notch2 shRNA-expressing cell lines (RAW-teton-shNotch1 and RAW-teton-
shNotch2). Tetracycline-resistant pcDNA6/TR-positive clones were used as par-
ent RAW cells.
RNAi assay. The RNAi assay was described previously (32). Three small
interference RNA (siRNA) molecules targeting RBPJ (siRBPJ) (Rbpsuh
Stealth Select 3 RNAi [MSS208567, MSS208565, and MSS208566]) were pur-
chased from Invitrogen. We used scrambled sequences as a negative control. We
used immunoblotting to validate the silencing effect on RBPJ.
DNA constructs. Constructs that activate Notch1 (N1ICOP) and Notch2
(N2ICOP) with a myc tag in pCS26MT have been previously described (1, 16).
The retroviral vector pMX-IRES-EGFP and Plat-E cells were kindly provided by
T. Kitamura (Tokyo University, Japan) (27, 44). The constructs were subcloned
FIG. 1. Notch is expressed and activated during osteoclast differ-
entiation. (A) BMM cells were treated with 50 ng/ml of RANKL for
the indicated times. Total RNA was isolated from BMMs, and expres-
sion levels of Notch1 to -4, Hes-1, RANK, cathepsin K, and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) mRNA were measured
by RT-PCR. (B) RANKL activates Notch signaling in BMMs. Total
cell lysates from RANKL-treated BMMs (50 ng/ml) were immuno-
blotted with anti-Notch1 or anti-Notch1 ICD (left) or anti-Notch2
(right) antibodies. The images of anti-Notch1 and anti-Notch1 ICD
were taken from the same membrane by reblotting. (C) Immunostain-
ing of Notch2 protein in BMMs stimulated with RANKL (50 ng/ml)
(top). The middle panels show nuclei stained with DAPI. The lower
panels show merged images of Notch2 and DAPI staining. Scale bar 
50 m. (D) Active form of Notch2 translocates to nuclei. BMMs were
treated with or without RANKL (50 ng/ml) for 30 min, and then
cytoplasm (C), membrane (M), and nuclear (N) extracts were pre-
pared and immunoblotted with anti-Notch2 antibodies. As fraction-
ation controls we used anti-IB antibodies for cytosol, anti-RANK
antibodies for the membrane, and anti-HDAC1 antibodies for the
nuclear fraction. Similar results were obtained in three independent
experiments.
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from the EcoRI/XhoI site of N1ICOP/pCS26MT and N2ICOP/pCS26MT
into the EcoRI/XhoI sites of pMX-IRES-EGFP, generating pMX-N1ICOP-
IRES-EGFP and pMX-N2ICOP-IRES-EGFP, respectively. Retrovirus packag-
ing was performed by transfecting the plasmids into Plat-E cells using Lipo-
fectamine 2000 (Invitrogen). Supernatants of pMX-N1ICOP-IRES-EGFP- and
pMX-N2ICOP-IRES-EGFP-transfected Plat-E cell culture medium were used
to infect primary BMMs in the presence of 8 g/ml Polybrene. The pCMX-N/
RBP-J construct was described elsewhere (20).
ChIP. Chromatin immunoprecipitation (ChIP) was performed with a ChIP
assay kit (Upstate Biotechnology) according to the manufacturer’s instructions
using antibodies against NFATc1, p50, p65, c-Fos, Notch2, RBPJ, and normal
immunoglobulin G. The purified DNA was analyzed by PCR using primers that
detect sequences containing the NFATc1-P1 promoter, 5-CCGGGACGCCCA
TGCAATCTGTTAGTAATT-3 (sense) and 5-GCGGGTGCCCTGAGAAAG
CTACTCTCCCTT-3 (antisense), and the Hes-1 promoter, 5-CACATCCTCT
TTACCTTGTTCCCTC-3 (sense) and 5-CCCTTTGCTAACTCTTTCCTCTG
G-3 (antisense).
Luciferase reporter assay. pNFATc1P1 0.8 kb-Luc (pNFATc1-pr-luc) was
constructed by inserting the pGL3 basic promoter vector according to the
method of Asagiri et al. (4). The RBPJ site mutation in the pNFATc1P1
promoter (pNFATc1-RBPJ mut-pr-luc) was constructed by PCR amplification
using the following primers: 5-ATTTAGCGGGAGGGGAATTTCC-3 (sense)
and 5-GGAAATTCCCCTCCCGCTAAAT-3 (antisense); the following prim-
ers were used to generate a mutation of the NF-	 binding site in the
pNFATc1P1 promoter (pNFATc1-RBPJ mut-pr-luc): 5-CGGGATGGGAAT
TTCGTTACTCCC-3 (sense) and 5-GGGAGTAACGAAATTCCCATCCCG-3
(antisense). The plasmids were transfected into RAW cells using Lipofectamine
2000 (Invitrogen), and luciferase activity was measured with the dual-luciferase
reporter assay system (Promega, Madison, WI).
Data analysis. Data are shown as mean values 
 standard errors of means
(SEM; n  number of culture wells). All experiments were performed at least
three times, and similar results were obtained. Statistical differences were ana-
lyzed using one-way analysis of variance, and P values less than 0.05 were
considered significant.
RESULTS
Notch is expressed and activated during osteoclast differ-
entiation. By microarray screening to identify mRNAs that
were differentially expressed in untreated versus RANKL-
treated RAW cells, a macrophage cell line that differentiates
into osteoclasts in response to RANKL, we found that several
Notch family members and Notch targets were upregulated
following RANKL stimulation, concomitant with the expres-
sion of osteoclast differentiation markers (Table 1). We con-
firmed these results for RANKL-stimulated BMMs using semi-
quantitative RT-PCR and found that expression of Notch2
mRNA was increased within 24 h after RANKL stimulation
(Fig. 1A) together with a weak induction of Notch1. The ex-
pression of the Hes-1 gene, a Notch target gene, was similar to
FIG. 2. GSI suppresses RANKL-induced osteoclastogenesis.
(A) Mouse bone marrow cells were treated with M-CSF (50 ng/ml) for
3 days in the presence of GSI and further cultured in the presence of
50 ng/ml RANKL together with GSI for 3 more days. (B) Mouse bone
marrow cells were treated with M-CSF for 3 days in the presence of
GSI. The culture medium was removed, and cells were washed with
phosphate-buffered saline twice and were further cultured in the pres-
ence of 50 ng/ml RANKL for 3 days. (C) Mouse bone marrow cells
were treated with M-CSF (50 ng/ml) for 3 days and further cultured in
the presence of RANKL (50 ng/ml) together with GSI for 3 days. Cells
were fixed and stained for TRAP. TRAP MNCs were counted as
osteoclasts. Scale bar  100 m. Data shown are the numbers of
TRAP MNCs per culture well (values are means 
 SEM, n  3).
Hes-1 and GAPDH mRNA expression levels were determined by
RT-PCR.
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that of Notch2, suggesting that Notch signaling was activated
during osteoclast differentiation induced by RANKL. On the
other hand, other Notch family members such as Notch3 and
Notch4 were undetectable in these cells (Fig. 1A). We next
examined the expression and cellular localization of Notch1
and Notch2 proteins in RANKL-treated BMMs undergoing
terminal differentiation of multinucleated osteoclasts. By
Western blotting and immunofluorescence, we detected the
presence of the intracellular active Notch2 form, N2ICD, at
24 h, and N2ICD was still present after 3 days of RANKL
treatment (Fig. 1B and C). To further demonstrate that
Notch2 was translocated into the nucleus following RANKL
stimulation, we obtained membrane, cytoplasmic, and nuclear
fractions from BMM cells and performed Western blot anal-
ysis with anti-Notch2 antibody. N2ICD was observed only in
the nuclear fractions after RANKL stimulation (Fig. 1D).
RANKL, IB, and HDAC1 were used to determine the pu-
rities of the different cellular fractions. In addition, total levels
of Notch2 protein in both membrane and nuclear fractions
were significantly increased after the RANKL stimulation
compared to those in untreated cells. These results indicated
that RANKL induced Notch2 protein expression and activated
Notch signaling during osteoclastogenesis.
GSI suppresses RANKL-induced osteoclastogenesis. To fur-
ther examine the role of Notch2 in osteoclast differentiation,
we added GSI, which blocks Notch signaling, to bone marrow
cell cultures together with RANKL and M-CSF. GSI inhibited
RANKL-induced osteoclastogenesis from bone marrow cells
and the expression of Hes-1 in a dose-dependent manner (Fig.
2A). It was previously shown that osteoclast differentiation
consists of at least two steps: (i) the proliferation of osteoclast
progenitors and their differentiation into osteoclast precursors
(BMMs) induced by M-SCF and (ii) the subsequent differen-
tiation of osteoclast precursors into osteoclasts induced by
RANKL (54). We examined which step was affected by GSI
treatment. Incubation with GSI together with M-CSF for 3
days and then further culture with RANKL gave rise to the
generation of numerous osteoclasts (Fig. 2B), whereas expres-
sion of Hes-1 did not change (Fig. 2B). However, when added
to the culture together with RANKL, GSI strongly inhibited
osteoclast formation together with the expression of Hes-1
(Fig. 2C). These findings suggest that Notch signaling is essen-
tial during the second wave of osteoclastogenesis, which is
mediated by RANKL.
Inhibition of RANKL-induced osteoclastogenesis by silenc-
ing Notch2 mRNA. We next examined whether specific loss of
function of Notch1 or Notch2 homologues affects osteoclast
formation. Since both Notch1- and Notch2-deficient mice die
at the early embryonic stage (37, 53), there is little information
about the physiological role of these proteins in bone devel-
opment. Thus, we generated RAW cell lines carrying tetracy-
cline-inducible shRNA that specifically targets the expression
of Notch1 or Notch2 (RAW-teton-shNotch1 or -shNotch2).
We confirmed that endogenous Notch1 and Notch2 expression
was suppressed in RAW-teton-shNotch1 and -shNotch2 cells
in response to tetracycline (Fig. 3A and B, right). We found
that RANKL-induced differentiation was not affected in
RAW-shNotch1 cells compared to the control cells (Fig. 3A).
In contrast, knocking down Notch2 expression significantly
inhibited osteoclast formation in RAW-teton-shNotch2 cells
(Fig. 3B).
The active form of Notch2 positively regulates RANKL-in-
duced osteoclastogenesis. To further investigate the role of
Notch signaling, we examined the effects of expressing the
active forms of Notch1 or Notch2 in BMMs. We constructed
pMX-N1ICOP-IRES-GFP and pMX-N2ICOP-IRES-EGFP,
which were engineered to express both active forms of Notch1
or Notch2 and green fluorescence protein (GFP) and infected
BMMs with the different constructs. Infection efficiency was
monitored by measuring GFP expression (Fig. 4A), and ex-
pression of ectopic Notch1 or Notch2 was detected by immu-
nostaining with the anti-Notch1 and -Notch2 intracellular do-
mains (ICDs) or the anti-myc tag antibodies (Fig. 4B). Ectopic
expression of activated Notch2 but not Notch1 in BMMs re-
sulted in efficient induction of osteoclast differentiation in a
RANKL dose-dependent manner (Fig. 4C).
FIG. 3. Inhibition of RANKL-induced osteoclastogenesis by silencing
Notch2 mRNA. Data for RAW cells with stable expression of tetracy-
cline-regulated expression of shRNAs (Tet-on) that target Notch1
(RAW-teton-shNotch1) (A) and Notch2 (RAW-teton-shNotch2) (B) are
shown. RAW-teton-shNotch1 and RAW-teton-shNotch2 cells were
treated with RANKL (20 ng/ml) for 3 days. TRAP MNCs were counted
as osteoclasts. Scale bar  100 m. The graph values are means 
 SEM
(n  3). Both RAW-teton-shNotch1 and RAW-teton-shNotch2 cells were
treated with or without tetracycline for 3 days. Total cell lysates were
immunoblotted with anti-Notch1 or anti-Notch1 ICD (A, right) or anti-
Notch2 (B, right) antibodies. -Actin is shown as a loading control. The
images of anti-Notch1 or anti-Notch1 ICD were taken from same mem-
brane by reblotting.
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Expression of Notch ligands in osteoclast precursors. Pre-
vious data showed RANKL induced not only Notch2 expression
but also activation of Notch signaling (Fig. 1B to D), thus sug-
gesting that RANKL regulates Notch ligand expression. There-
fore, we examined the expression of Notch ligands in RANKL-
treated BMMs and found that Jagged1 expression gradually
increased from day 1 (1.23-fold) to day 3 (3.21-fold) of treatment
(Fig. 5A). To determine whether Jagged1 was responsible for
activating Notch2 during osteoclast differentiation, we incubated
BMMs or RAW-teton-shNotch2 cells with either soluble recom-
binant FLAG-Jagged1 or Jagged1 immobilized on the culture
plate. We found that Jagged1 enhanced RANKL-induced osteo-
clastogenesis in both culture conditions (Fig. 5B). As a control,
addition of tetracycline inhibited RANKL-dependent osteoclast
formation from RAW-teton-shNotch2 (Fig. 5C), but not RAW-
teton-shNotch1, cells (data not shown) incubated with FLAG-
Jagged1. Even though we cannot exclude the possibility that other
RANKL-induced effects also affect Notch activation, these results
strongly suggest that Jagged1 activates Notch signaling via Notch2
and that this activation enhanced the osteoclast formation in-
duced by RANKL.
Notch2 modulates RANKL-induced osteoclastogenesis
through NFATc1. To investigate the molecular mechanisms by
which Notch signaling enhances osteoclast formation induced
by RANKL, we examined the expression of NFATc1, a master
regulator of osteoclastogenesis (4, 55). NFATc1 was induced in
BMMs at 24 h after RANKL stimulation (Fig. 6A). Activation
of Notch signaling by Jagged1 or by ectopic expression of
N2ICD enhances NFATc1 expression (Fig. 6A). Conversely,
inhibition of Notch signaling by GSI or shRNA for Notch2
strongly suppressed NFATc1 expression (Fig. 6A). These re-
sults suggest that Notch modulates RANKL-induced NFATc1
expression. Analysis of the NFATc1 promoter revealed the
presence of a putative RBPJ binding site overlapping an
NF-B site (Fig. 6B). ChIP analysis showed that Notch2 was
recruited to the NFATc1 promoter after 30 min of RANKL
stimulation, reached a maximum level at 1 h, and declined
after 6 h of treatment (Fig. 6C). In contrast, we found that
FIG. 4. The active form of Notch2 positively regulates RANKL-
induced osteoclastogenesis. BMMs were transduced with N1ICOP,
N2ICOP, or empty pMX-IRES-EGFP retroviral vectors. (A) Images
of GFP MNCs from BMM cells induced by RANKL stimulation.
Scale bar  100 m. (B) Total cell lysates were immunoblotted with
anti-Notch1, -Notch2, and -myc antibodies or anti--actin as a loading
control. (C) Transduced BMMs were treated with RANKL (0, 25, or
50 ng/ml) for 3 days. TRAP MNCs were counted as osteoclasts. The
values are means 
 SEM (n  3).
FIG. 5. Expression of Notch ligands in osteoblasts and osteoclast
precursors. (A) Expression of Notch ligand-related genes in mice
treated with RANKL (50 ng/ml). Total RNA was isolated from osteo-
blasts or BMMs, and expression levels of indicated genes were mea-
sured by RT-PCR. (B) BMMs were treated with RANKL (50 ng/ml) in
the presence of soluble FLAG-fused Jagged1 (Jagged-1 FL) (0.5, 1, or
2 g/ml) for 3 days. (C) RAW-teton-shNotch2 cells were treated with
RANKL (20 ng/ml) in the presence of either the soluble form or
immobilized Jagged1 for 3 days with or without tetracycline. TRAP
MNCs were counted as osteoclasts. Values are means 
 SEM (n  3).
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FIG. 6. Molecular mechanisms by which Notch modulates RANKL-induced osteoclastogenesis. (A) Expression of NFATc1 induced by
RANKL in mouse BMMs in the presence of soluble Jagged1, transduced Notch2, shRNA for Notch2, or GSI. Cells were treated with RANKL
(50 ng/ml) for the indicated times. Total cell lysates were immunoblotted with anti-NFATc1 antibody. IB, immunoblotting. (B) Schematic
representation of the NFATc1 P1 promoter. The sequences of the NF-B binding site and the overlapping putative RBPJ binding site are shown.
(C) Chromatin from RANKL-treated BMMs was precipitated using the indicated antibodies. The NFATc1 promoter was amplified by PCR from
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RBPJ was in the NFATc1 promoter before RANKL stimu-
lation and that RBPJ was undetectable at 30 min and 3 h after
RANKL stimulation, coinciding with Notch2 recruitment. It
has been recently reported that RANKL-induced NF-B ac-
tivity is important for the initial induction of NFATc1 in the
early stage of osteoclastogenesis and that c-Fos recruitment to
the NFATc1 promoter is important in the autoamplification
phase of NFATc1 induction (4). Consistent with this, we found
that both p50 and p65 NF-B subunits were recruited to the
NFATc1 promoter within 30 min after RANKL stimulation
while NFATc1 and c-Fos were recruited to the promoter after
6 h (Fig. 6C). These data suggest the possibility that NF-B
and Notch2 cooperate in the activation of NFATc1 expression.
In agreement with this, coimmunoprecipitation experiments
demonstrated that Notch2 physically interacts with p65 in the
nucleus in a RANKL-dependent manner (Fig. 6D). Next, we
generated luciferase reporter constructs containing specific
mutations in the NF-B (NF-B-mut) or RBPJ (RBPJ-mut)
binding sites of the NFATc1 promoter. Cotransfection of
Notch2 with p65 enhanced NFATc1 promoter activity com-
pared with transfection with Notch2 alone in both the wild-
type and the RBPJ-mut constructs (Fig. 6E). In contrast,
Notch2 alone or in combination with p65 failed to activate the
NF-B-mut promoter (Fig. 6E), suggesting that p65 plays an
essential role in Notch2-mediated activation of the NFATc1
gene. To further study the putative role of RBPJ in the
regulation of NFATc1 expression, we transfected RBPJ to-
gether with Notch2 or Notch2/p65 and then measured lucifer-
ase activity. In both conditions RBPJ strongly suppressed
NFATc1 promoter activity (Fig. 6F), suggesting that RBPJ
may compete with p65 for DNA binding. We next examined
the binding of endogenous p65 and RBPJ to the NFATc1
promoter in the absence of Notch2 using RAW-teton-
shNotch2 cells. Interestingly, we found that RBPJ constitu-
tively bound the NFATc1 promoter in these conditions (Fig.
6G). In a reciprocal experiment, knocking down RBPJ ex-
pression using specific siRNA slightly enhanced binding of p65
and Notch2 to the NFATc1 promoter (Fig. 6H). These results
indicate that NFATc1 is downstream of both Notch2 and
NF-B during RANKL-mediated osteoclast differentiation.
Altogether, these results demonstrate an essential role for
Notch2 in the induction of the terminal osteoclast differentia-
tion.
DISCUSSION
Notch signaling has been implicated in various processes
including cell fate decisions, tissue patterning, and morpho-
genesis (3, 9). Using genome-wide screening techniques and
RT-PCR results, we found that Notch2 and Jagged1 are up-
regulated during RANKL-induced osteoclastogenesis, suggest-
ing that Notch modulates downstream of RANK signaling.
Consistently, inhibition of Notch signaling using GSI or
shRNA for Notch2, but not Notch1, decreased NFATc1 ex-
pression, resulting in inhibition of osteoclastogenesis. We dem-
onstrate that NFATc1 is a direct target of the Notch2–NF-B
complex in response to RANKL stimulation.
Our current results are in apparent contradiction with a
previous study showing that activation of Notch by Delta1
negatively regulated osteoclastogenesis by reducing the surface
levels of c-Fms in osteoclast precursor cells together with en-
hanced osteoprotegerin expression in stromal cells (62) and
with the work from Bai et al. demonstrating that deletion of
Notch1 to -3 enhances osteoclast commitment from bone mar-
row precursors (6). In fact, several reports support the idea
that the requirement for Notch strongly depends on the stage
of osteoclast differentiation and the type of the cells that are
targeted. Recently, it was found that specific deletion of pre-
senilin 1 and 2 in the skeletogenic mesenchyme led to in-
creased trabecular bone mass. Furthermore, deletion of both
Notch1 and -2 under the control of Prx-Cre produced a post-
natal skeletal phenotype qualitatively identical to that of pre-
senilin 1 and 2 double-knockout mice. However, deletion of
Notch1 and -2 in committed osteoblasts using Col1-Cre did not
result in any obvious skeletal phenotype (21). We believe that
Notch2 is specifically required for the late stage of osteoclast
differentiation, which is mediated by RANKL, but not for the
initial phase, which is dependent on M-CSF, as was shown by
deletion of Notch1 and -3 under the control of lyzM-Cre (6).
Our results also show a very specific requirement for Notch2 in
RANKL-induced osteoclast differentiation, which in collabo-
ration with NF-B regulates NFATc1 expression in wild-type
cells; this is in apparent contradiction with the enhanced osteo-
clast differentiation that occurs in the triple-knockout cells (6).
We speculate that deletion of all Notch receptors in early
differentiation stages of the myeloid cell lineage may activate
different transcriptional complexes and result in enhanced os-
teoclastogenesis in the triple-knockout mice.
Different expression patterns of Notch and Notch ligands
together with the microarray data from RANKL-treated cells
suggest that specific ligand-receptor pairs may play specific
functions during osteoclast differentiation. Although there are
no major functional disparities between Delta and Jagged or
between the different Notch homologues in vitro, these pro-
teins show distinct expression patterns (34, 60) and different,
nonredundant in vivo functions (39). We here demonstrated
that Jagged1 is specifically activated in response to RANKL
precipitated DNA and from 1% of the input to monitor the amount of chromatin used. (D) Interaction of Notch2 and p65 in BMMs upon RANKL
stimulation. Nuclear extracts from RANKL-treated BMMs were immunoprecipitated (IP) with anti-Notch2 antibodies and processed for immu-
noblotting with anti-p65 antibodies. The membrane was stripped and reblotted with anti-Notch2 antibodies to determine the amount of
precipitated proteins. (E) RAW cells were transfected with the NFATc1 p1 promoter and the indicated plasmids and assayed for luciferase activity
after 24 h. (F) Luciferase activity of NFATc1 p1 when cotransfected with the indicated plasmids in RAW cells. (G) ChIP assay with anti-p65,
anti-Notch2, anti-RBPJ, or control immunoglobulin G from RAW-teton-shNotch2 cells treated with RANKL with or without tetracycline.
Analysis of the NFATc1 promoter was performed by PCR. (H) Chromatin treated with RANKL from RAW cells with knocked down RBPJ
expression was precipitated with the indicated antibodies. The NFATc1 promoter was amplified from precipitated DNA and 1% of the input by
PCR. Similar results were obtained in three independent experiments.
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treatment, thus inducing Notch2 activation in BMMs. As an
additional mechanism, RANKL might directly induce Notch2.
Alternatively, previous reports show increased Jagged1 expres-
sion in the osteoblastic stromal cells of PTH/PTHrP receptor
transgenic mice (10, 11). We speculated that the source of
Jagged1 during osteoclastogenesis is RANKL-stimulated
BMMs as well as osteoblastic stromal cells. Moreover, Notch1
cannot compensate for Notch2 deficiency in RANKL-depen-
dent osteoclast differentiation, in that the knockdown of
Notch2 using shRNA absolutely eliminates the effects of
Jagged1. These results are in agreement with the different roles
for Notch1 and Notch2 in myeloid cell differentiation induced
by granulocyte colony-stimulating factor or granulocyte-mac-
rophage colony-stimulating factor (7). Another example show-
ing that two different Notch ligands generate distinct responses
in the same cell type has been recently published: Delta pro-
motes Th1 responses, while Jagged instructs the Th2 lineage in
naive CD4 T cells (2).
In this study, we demonstrated that, like the Notch2 ICD,
Jagged1 enhanced RANKL-induced osteoclastogenesis. A pre-
vious report demonstrated that immobilized Notch ligand Del-
ta1, but not soluble Delta1, induced Hes-1 gene expression or
suppressed the differentiation from osteoclast precursors in-
duced by M-CSF (62). We cannot explain the reasons under-
lying the reported controversial effects for the soluble and
immobilized ligands; however, we speculate that experimental
conditions and protein stability are crucial for success in the
use of these molecules. In fact, soluble Jagged1 ligand or pep-
tides have been extensively reported (26, 33, 42, 59). In this
study, we found that both soluble and immobilized Jagged1
enhanced RANKL-induced osteoclastogenesis under the cul-
ture conditions of Yamada et al. (62) and that this effect was
strictly dependent on Notch2.
Specific regulation of gene transcription is the combina-
torial effect of multiple transcription factors. In this study,
we identified a canonical RBPJ site within the mouse
NFATc1 P1 promoter that overlaps an NF-B site. Based on
the recognition sequence for RBPJ (G/ATGGGAA), the
occurrence of dual NF-B/RBPJ elements is predicted to
occur at 15% of the NF-B sites, which are the ones that
contain the GGGAA NF-B half-site (22, 31). This element,
which is similar to those present in the IL-6, beta interferon,
Hes-1, p52/NF-B2, IB, and Bcl-3 genes, may define a
distinct subclass of genes regulated by Notch and NF-B (1,
16, 17, 45, 49, 58). We have found that RANKL induces
association of NF-B and Notch2 in the nucleus and that
both NF-B and Notch2 bind to the NFATc1 promoter in
these conditions concomitant with reduced detection of
RBPJ. This result suggests that p65 functionally competes
for RBPJ binding to activate transcription; however, an
alternative explanation could be that a ternary complex in-
volving p65, Notch2, and RBPJ may mask the epitope
involved in antibody recognition. We demonstrated that the
inhibition of Notch signaling by GSI leads to a dramatic
decrease in RANKL-induced osteoclastogenesis by inhibit-
ing NFATc1 expression. A comparable effect was observed
by inhibiting endogenous expression of Notch2 with shRNA
for Notch2 but not by inhibition of Notch1 by shRNA for
Notch1. The fact that cross talk between the NF-B and
Notch pathways promotes synergistic signaling effects (16,
17, 45, 49, 58) suggests that Notch2 enhances NF-B tran-
scriptional activity. In addition, we have showed that
RANKL induced Notch2 expression and activation. These
data suggest that Notch2, like NFATc1, functions as an
autoamplification factor in response to RANKL signaling.
Further studies are required to determine the role of the
molecular mechanism of Notch signaling in osteoclast dif-
ferentiation.
In conclusion, we have shown in this study that RANKL
induced Jagged1 and Notch2 expression during osteoclast dif-
ferentiation. Moreover, inhibition of Notch2 signaling strongly
suppressed, whereas ectopic expression of N2ICD enhanced,
RANKL-induced osteoclastogenesis. Activated Notch2 coop-
erates with NF-B to activate NFATc1 transcription, which is
an important mediator of osteoclast maturation. These find-
ings may provide a therapeutic opportunity to specifically tar-
get osteoclast activation in pathological situations.
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